Evidence of a novel site mediating anandamide‐induced negative inotropic and coronary vasodilatator responses in rat isolated hearts

Evidence of a novel site mediating anandamide‐induced negative inotropic and coronary... Cannabinoids are known to cause coronary vasodilatation and reduce left ventricular developed pressure (LVDP) in isolated hearts although the identity of the receptor(s) mediating these responses is unknown. Our objective was to pharmacologically characterize cannabinoid receptors mediating cardiac responses to the endocannabinoid, anandamide. Dose‐response curves for coronary perfusion pressure (CPP) and LVDP were constructed to anandamide, R‐(+)‐methanandamide, palmitoylethanolamide (PEA) and JWH015 in isolated Langendorff‐perfused rat hearts. Anandamide dose‐response curves were also constructed in the presence of antagonists selective for CB1, CB2 or VR1 receptors. Anandamide and methanadamide significantly reduced CPP and LVDP but the selective CB2 receptor agonists, PEA and JWH015 had no significant effect, compared with equivalent vehicle doses. Single bolus additions of the selective CB1‐receptor agonist, ACEA (5 nmol), decreased LVDP and CPP. When combined with JWH015 (5 nmol) these responses were not augmented. Anandamide‐mediated reductions in CPP were significantly blocked by the selective CB1 receptor antagonists SR 141716A (1 μM) and AM251 (1 μM) and the selective CB2 receptor antagonist SR 144528 (1 μM) but not by another selective CB2 receptor antagonist AM630 (10 μM) nor the vanilloid VR1 receptor antagonist capsazepine (10 μM). SR 141716A, AM281 and SR 144528 significantly blocked negative inotropic responses to anandamide that were not significantly affected by AM251, AM630 and capsazepine. One or more novel sites mediate negative inotropic and coronary vasodilatatory responses to anandamide. These sites can be distinguished from classical CB1 and CB2 receptors, as responses are sensitive to both SR 141716A and SR 144528. British Journal of Pharmacology (2002) 135, 1191–1198; doi:10.1038/sj.bjp.0704565 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Pharmacology Wiley

Evidence of a novel site mediating anandamide‐induced negative inotropic and coronary vasodilatator responses in rat isolated hearts

Loading next page...
 
/lp/wiley/evidence-of-a-novel-site-mediating-anandamide-induced-negative-7ViveC4wyN
Publisher
Wiley
Copyright
2002 British Pharmacological Society
ISSN
0007-1188
eISSN
1476-5381
D.O.I.
10.1038/sj.bjp.0704565
Publisher site
See Article on Publisher Site

Abstract

Cannabinoids are known to cause coronary vasodilatation and reduce left ventricular developed pressure (LVDP) in isolated hearts although the identity of the receptor(s) mediating these responses is unknown. Our objective was to pharmacologically characterize cannabinoid receptors mediating cardiac responses to the endocannabinoid, anandamide. Dose‐response curves for coronary perfusion pressure (CPP) and LVDP were constructed to anandamide, R‐(+)‐methanandamide, palmitoylethanolamide (PEA) and JWH015 in isolated Langendorff‐perfused rat hearts. Anandamide dose‐response curves were also constructed in the presence of antagonists selective for CB1, CB2 or VR1 receptors. Anandamide and methanadamide significantly reduced CPP and LVDP but the selective CB2 receptor agonists, PEA and JWH015 had no significant effect, compared with equivalent vehicle doses. Single bolus additions of the selective CB1‐receptor agonist, ACEA (5 nmol), decreased LVDP and CPP. When combined with JWH015 (5 nmol) these responses were not augmented. Anandamide‐mediated reductions in CPP were significantly blocked by the selective CB1 receptor antagonists SR 141716A (1 μM) and AM251 (1 μM) and the selective CB2 receptor antagonist SR 144528 (1 μM) but not by another selective CB2 receptor antagonist AM630 (10 μM) nor the vanilloid VR1 receptor antagonist capsazepine (10 μM). SR 141716A, AM281 and SR 144528 significantly blocked negative inotropic responses to anandamide that were not significantly affected by AM251, AM630 and capsazepine. One or more novel sites mediate negative inotropic and coronary vasodilatatory responses to anandamide. These sites can be distinguished from classical CB1 and CB2 receptors, as responses are sensitive to both SR 141716A and SR 144528. British Journal of Pharmacology (2002) 135, 1191–1198; doi:10.1038/sj.bjp.0704565

Journal

British Journal of PharmacologyWiley

Published: Mar 1, 2002

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off